Biomarkers /
HLF
Overview
Hepatic leukemia factor (HLF) is a gene that encodes a protein that functions as a transcriptional activator. Fusions, missense mutations, silent mutations are observed in cancers such as intestinal cancer and ovarian cancer.
HLF is altered in 0.10% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, and esophageal adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in HLF are HLF A254T (0.22%), HLF E2Q (0.39%), HLF M86I (0.22%), HLF R275S (0.39%), and HLF R6Q (0.22%) [3].
Clinical Trials
Significance of HLF in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.